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Whether thyroid dysfunction plays a causal role in the development of cancer remains inconclusive. We conducted a two-
sample Mendelian randomization study to investigate the associations between genetic predisposition to thyroid dysfunction
and 22 site-specific cancers. Single-nucleotide polymorphisms associated with four traits of thyroid function were selected
from a genome-wide association meta-analysis with up to 72,167 European-descent individuals. Summary-level data for breast
cancer and 21 other cancers were extracted from the Breast Cancer Association Consortium (122,977 breast cancer cases and
105,974 controls) and UK Biobank (367,643 individuals). For breast cancer, a meta-analysis was performed using data from
both sources. Genetically predicted thyroid dysfunction was associated with breast cancer, with similar patterns of
associations in the Breast Cancer Association Consortium and UK Biobank. The combined odds ratios of breast cancer were
0.94 (0.91–0.98; p = 0.007) per genetically predicted one standard deviation increase in TSH levels, 0.96 (0.91–1.00;
p = 0.053) for genetic predisposition to hypothyroidism, 1.04 (1.01–1.07; p = 0.005) for genetic predisposition to
hyperthyroidism and 1.07 (1.02–1.12; p = 0.003) per genetically predicted one standard deviation increase in free thyroxine
levels. Genetically predicted TSH levels and hypothyroidism were inversely with thyroid cancer; the odds ratios were 0.47
(0.30–0.73; p = 0.001) and 0.70 (0.51–0.98; p = 0.038), respectively. Our study provides evidence of a causal association
between thyroid dysfunction and breast cancer (mainly ER-positive tumors) risk. The role of TSH and hypothyroidism for
thyroid cancer and the associations between thyroid dysfunction and other cancers need further exploration.
Introduction
Subclinical thyroid dysfunction is defined as abnormal serum
thyroid-stimulating hormone (TSH) levels with physiologi-
cally normal free thyroxine levels in asymptomatic patients1
and is a common disorder among adults,2 particularly in older
women.2 Considering the important role of thyroid hormones
in cell proliferation and differentiation, thyroid dysfunction
has been proposed as a potential and preventable risk factor
for cancer, such as thyroid3,4 and breast cancer.5,6
Observational data on the associations between thyroid
dysfunction and risk of cancer are conflicting. Low TSH levels
were associated with an increased risk of thyroid carcinoma in
one study,3 while it was stated that higher TSH levels were
associated with a higher frequency and more advanced stage
of thyroid cancer in another study.7 With regard to breast
cancer, a meta-analysis of 13 case–control studies published
until June 2016 found no association between hypothyroidism
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or hyperthyroidism and breast cancer risk.8 However, results
from a nationwide population-based cohort study in Denmark
showed that women diagnosed with hypothyroidism and
hyperthyroidism had respectively lower and higher risk of
breast cancer compared to the general population.9 Similarly,
hyperthyroidism was associated with a significant increased
risk of breast cancer mortality in a prospective cohort study of
75,076 US women.10 A limitation of available evidence is that
observational findings are prone to be influenced by residual
confounding and reverse causality, thereby impeding the
causal inference on association between thyroid dysfunction
and cancer risk.
Genetic variants explicitly associated with a potential risk
factor (e.g., TSH levels) can be used as unbiased proxies for
the risk factor to determine causality. This approach, named
as Mendelian randomization (MR), is a genetic method that
can strengthen the inference on the causal nature of exposure-
outcome associations by diminishing the likelihood of con-
founding and eliminating reverse causality in conventional
observational studies.11 This is because the genetic alleles asso-
ciated with the exposure are randomly assorted at conception
and thus unrelated to self-selected lifestyle and environmental
factors and are not modified by disease. Given the controversy
and uncertainty of the role of thyroid dysfunction for cancer,
we conducted a two-sample Mendelian randomization study
to explore the causal associations of four indicators of thyroid
function and dysfunction, including circulating TSH levels,
hypothyroidism, hyperthyroidism and free thyroxine levels,
with overall cancer and 22 site-specific cancers.
Materials and Methods
Assumptions of MR study and study design overview
There are three key assumptions for MR analysis: (i) the
genetic variants used as instrumental variables should be
robustly associated with the risk factor of interest (Relevance
assumption); (ii) the used genetic variants should not be asso-
ciated with potential confounders (Independent assumption);
and (iii) the genetic variants should affect the risk of the
outcome only through the risk factor, not via alternative path-
ways (Exclusion restriction assumption). The present two-
sample MR study was based on summary-level data from the
ThyroidOmics Consortium,12 the Breast Cancer Association
Consortium (BCAC)13 and the UK Biobank14 (Supporting
Information Table S1). Assumptions of MR study and study
design are shown in Figure 1. The original genome-wide asso-
ciation studies (GWASs) had been approved by corresponding
ethical committee and all participants provided informed con-
sent. The present study was approved by the Swedish Ethical
Review Authority.
Instrumental variable selection
Single-nucleotide polymorphisms (SNPs) associated with TSH
(n = 61), hypothyroidism (n = 8), hyperthyroidism (n = 8)
and free thyroxine levels (n = 31) at the genome-wide signifi-
cance level (p < 5 × 10−8) were identified from a meta-analysis
of GWASs of thyroid function and dysfunction with up to
72,167 individuals of European ancestry in both discovery and
replication stages12 (Supporting Information Table S1). One
TSH-related SNP located in the ABO locus was excluded due
to pleiotropic effects (blood group is associated with many
cancers,15,16 through effects independent of TSH), leaving
60 SNPs as instrumental variables for TSH levels. An SNP in
the GLIS1 gene showed genome-wide significant association
with both TSH and free thyroxine, and SNPs in FOXE1,
PDE8B and PDE10A locus were associated with both hyper-
thyroidism and hypothyroidism. In addition, the original
GWAS verified the associations of TSH and free thyroxine
level with hyperthyroidism and hypothyroidism using a
genetic risk score.12 Proxy SNPs were chosen at R2 > 0.9
among CEU population by searching in the dataset of Divi-
sion of Cancer Epidemiology and Genetics, National Cancer
Institute.17 We harmonized all instrumental variables for each
trait so that the effect alleles reflected the allele associated with
an increased probability or level of exposure. All used SNPs
were uncorrelated (R2 < 0.01) and details of the included
SNPs are displayed in Supporting Information Table S2.
Outcome data sources
Summary-level data for the associations of the thyroid-
associated SNPs with breast cancer were obtained from
BCAC, including 228,951 individuals of European ancestry
(122,977 breast cancer cases and 105,974 controls)13 and UK
Biobank14 with 13,666 breast cancer cases. The GWAS based
on the BCAC used 1000 Genomes Project (Phase 3) reference
panel in imputation stage and adjusted for genetic principal
components and country. From UK Biobank, summary-level
data for the SNP-cancer associations were also derived for
overall cancer and additionally 21 site-specific cancers using
What’s new?
Whether thyroid dysfunction plays a causal role in the development of cancer remains inconclusive. This two-sample
Mendelian randomization study investigated the associations between genetic predisposition to thyroid dysfunction and
22 site-specific cancers. Evidence of a causal inverse association was found between thyroid-stimulating hormone levels and
overall cancer. Increased thyroid-stimulating hormone levels and hypothyroidism were associated with decreased risk of
thyroid and breast (mainly ER-positive) cancer, whereas hyperthyroidism and increased free thyroxine levels were associated
with a higher risk of breast (mainly ER-positive) cancer. The results suggest that treatment of subclinical and diagnosed
hyperthyroidism may be an efficient cancer prevention strategy.
2 Thyroid dysfunction and cancer
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logistic regression models adjusted for age, sex and 10 genetic
principal components. The analyses of UK Biobank were
based on 367,643 participants after exclusion of related indi-
viduals (third-degree relatives or closer), low call rate and
excess heterozygosity (3 or more standard deviations from the
mean). Follow-up was until March 31, 2017, or death, and in
total 75,037 cancer cases were included.
Statistical analysis
The Wald method was used to estimate the ratio between the
SNP-outcome and SNP-exposure estimates for each SNP. The
ratio estimates for every used SNPs for one trait were com-
bined by using the fixed-effects or multiplicative random-
effects inverse-variance weighted meta-analysis method. The
inverse-variance weighted method can provide the most pre-
cise estimates but could be influenced by invalid instrumental
variables and pleiotropic effects. Thus, for overall cancer as
well as associations reaching the conventional significance
level (p < 0.05), we further conducted three sensitivity analyses
based on the weighted median, MR-Egger and MR-pleiotropy
residual sum and outlier (MR-PRESSO) methods to examine
and correct for possible pleiotropy. The weighted median
method gives accurate estimates if at least 50% of the instru-
mental variables are valid.18 The MR-Egger regression can
detect and adjust for pleiotropy albeit with low power.19 The
MR-PRESSO test can detect possible outliers and estimations
obtained from the MR-PRESSO analysis are corrected for hor-
izontal pleiotropy via outlier removal.20 To increase the power
for the analysis of breast cancer, a meta-analysis with fixed
effects was performed to combine the data from the BCAC
and UK Biobank. Odds ratios (ORs) of cancer risk were scaled
to one standard deviation (SD) increase in genetically
predicted TSH and free thyroxine levels and one-unit increase
in the log OR of hypothyroidism and hyperthyroidism in all
analyses. All statistical analyses were two-sided and performed
in Stata/SE 15.0 and R 3.6.0 software. We did not use p values
strictly to define statistical significance but interpreted the
results based on the patterns of associations across the
thyroid-related traits and the strengths of the associations.21
Data availability
Data for thyroid function can be obtained from the GWAS
(accession code phs000930 in dbGaP, http://locuszoom.sph.
umich.edu/genform.php).12 Summary-level data from BCAC13
are publicly available (http://bcac.ccge.medschl.cam.ac.uk/).
UK Biobank14 data are available through application (https://
www.ukbiobank.ac.uk/). Summary-level data for the used
SNPs in the present study are available upon a reasonable
request to the corresponding author.
Results
Seven of the thyroid-associated SNPs were unavailable in the
UK Biobank dataset. Proxy SNPs were found for four SNPs,
resulting in 58 SNPs in the analyses of TSH, 7 SNPs in the
analyses of hypothyroidism, 8 SNPs in the analyses of hyper-
thyroidism and 31 SNPs in the analyses of free thyroxine.
One SNP for TSH was not available in the dataset of the
BCAC and no suitable proxy was found.
Genetically predicted TSH levels showed a consistent asso-
ciation with overall cancer across the different MR methods
Figure 1. Assumptions of MR study and study design overview. [Color figure can be viewed at wileyonlinelibrary.com]
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(Fig. 2). The OR was 0.93 (95% confidence interval [CI],
0.91–0.96; p = 2.28 × 10−6) per one standard deviation increase
in TSH levels in the inverse variance weighted analysis. Results
for genetic liability to hypothyroidism and hyperthyroidism were
directionally consistent with those for TSH levels but less precise;
in particular, the results from the MR-Egger analyses were very
imprecise, indicative of very low power of this method.
Genetically predicted TSH and free thyroxine levels as well as
genetic predisposition to thyroid dysfunction were associated
with breast cancer, with similar patterns of associations in the
BCAC and UK Biobank (Table 1 and Fig. 3). In the meta-
analysis combining the results from the BCAC and UK Biobank
(136,643 breast cancer cases and 459,951 noncases), the com-
bined ORs of breast cancer were 0.94 (95% CI 0.91–0.98;
p = 0.007) per genetically predicted one SD increase in TSH
levels, 0.96 (95% CI, 0.91–1.00; p = 0.053) per one-unit increase
in log odds of hypothyroidism, 1.04 (95% CI, 1.01–1.07;
p = 0.005) per one-unit increase in log odds of hyperthyroidism
and 1.07 (95% CI, 1.02–1.12; p = 0.003) per genetically predicted
one SD increase in free thyroxine levels (Fig. 3). The OR esti-
mates were similar but less precise in the sensitivity analyses
(Supporting Information Fig. S1). There was suggestive evidence
that thyroid dysfunction, in particular hyperthyroidism and free
thyroxine levels, was associated with estrogen-receptor
(ER) positive but not negative tumors (Table 1).
Genetically higher TSH levels and liability to hypothyroid-
ism were associated with lower odds of thyroid cancer
(Table 1 and Fig. 4). For one SD increase of TSH levels and
one-unit increment of the log odds of hypothyroidism, the
ORs of thyroid cancer were 0.47 (0.30–0.73; p = 0.001) and
0.70 (0.51–0.98; p = 0.038), respectively. Significant heteroge-
neity (I2 = 39; p = 0.002) among estimates of individual SNPs
was detected in the analysis of TSH. After removal of two out-
liers, the magnitude and the significance of the association
between TSH and thyroid cancer remained in the MR-PRESSO
analysis (OR = 0.48, 0.32–0.77; p = 0.001; Fig. 4). The associa-
tions were similar in sensitivity analyses using the weighted
median and MR-Egger methods (Fig. 4).
There was no clear pattern of associations of genetically
predicted thyroid dysfunction with the other 20 cancers stud-
ied (Table 1). Nevertheless, there was suggestive evidence of
inverse associations of genetically predicted TSH levels with
uterine and prostate cancer; an inverse association between
genetic liability to hyperthyroidism and brain cancer; and
inverse associations between free thyroxine levels and ovarian
and bladder cancer and melanoma.
Figure 2. Associations of genetically predicted TSH and free thyroxine levels, hypothyroidism and hyperthyroidism with overall cancer in UK
Biobank with 75,037 cancer cases at any site. Heterogeneity was observed in the analysis of hypothyroidism and hyperthyroidism. There was
no detected pleiotropy in all MR-Egger analyses. Two and one outliers were detected and corrected in the MR-PRESSO analysis of
hypothyroidism and hyperthyroidism, respectively. No outlier was detected in the analysis of TSH and free thyroxine. Abbreviations: CI,
confidence interval; IVW, inverse-variance weighted; MR-PRESSO, Mendelian randomization-pleiotropy residual sum and outlier; OR, odds
ratio; TSH, thyroid-stimulating hormone.
4 Thyroid dysfunction and cancer
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Discussion
In the present study, we found evidence of a causal inverse asso-
ciation between TSH levels and overall cancer. Furthermore,
increased TSH levels and hypothyroidism were associated with a
decreased odds of breast cancer (mainly ER-positive tumors)
and thyroid cancer, whereas hyperthyroidism and increased free
thyroxine levels were associated with a higher odds of breast
cancer (mainly ER-positive tumors). We found limited evidence
supporting causal associations of thyroid dysfunction with
20 other cancers.
Figure 4. Associations of genetically predicted TSH and free thyroxine levels, hypothyroidism and hyperthyroidism with thyroid cancer.
Heterogeneity was observed in the analysis of TSH, hyperthyroidism and free thyroxine. There was no detected pleiotropy in all MR-Egger
analyses. Two, one and two outliers were detected and corrected in the MR-PRESSO analysis of TSH, hyperthyroidism and thyroxine,
respectively. Abbreviations: CI, confidence interval; IVW, inverse-variance weighted; MR-PRESSO, Mendelian randomization-pleiotropy
residual sum and outlier; OR, odds ratio; TSH, thyroid-stimulating hormone.
Figure 3. Meta-analysis of the associations of genetically predicted TSH and free thyroxine levels, hypothyroidism and hyperthyroidism with
breast cancer. Abbreviations: BCAC, Breast Cancer Association Consortium; CI, confidence interval; TSH, thyroid-stimulating hormone; OR,
odds ratio; UKBB, UK Biobank. [Color figure can be viewed at wileyonlinelibrary.com]
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Observational studies have found that thyroid disorder and
thyroid hormone levels were related to risk of overall
cancer.10,22–24 Consistent with our findings, a 9-year cohort
study of 29,691 individuals without previously known thyroid
disease found that participants with low TSH levels had
increased cancer risk compared to the euthyroid reference
group after adjustment of age, sex and smoking status.24
Another cohort study of 75,076 US women and 30-year
follow-up period showed that women with hyperthyroidism
had an elevated risk of cancer, especially breast and ovarian
cancer.10 In contrast, a cohort study of 115,746 Asians found
that subclinical hypothyroidism was associated with increased
cancer mortality over a 10-year follow-up period.25
In line with our MR results, most observational prospective
studies have found that hypothyroidism is associated with a
lower risk of breast cancer,9,26 whereas hyperthyroidism9,10
and high free thyroxine levels5,27,28 are associated with an
increased breast cancer risk, especially among overweight27
and postmenopausal women.28 TSH levels were inversely
associated with breast cancer risk in one study28 but not in
two other.5,27 On the contrary, two meta-analyses based on
data from 12 or 13 case–control studies showed no association
of hypothyroidism or hyperthyroidism with odds of breast
cancer.8,29 The inconsistency among studies may be attribut-
able to reverse causation bias in the case–control studies, mea-
surement bias (causing dilution of the effect), or inadequate
power. In this MR study, results for thyroid function in rela-
tion to breast cancer were in the same direction in the BCAC
and UK Biobank albeit less precise in UK Biobank. When
combining the results from the two data sources, thereby
increasing the sample size, all associations became statistically
significant. In the present study, based on data from the
BCAC, the associations of thyroid function and dysfunction
with breast cancer risk were mainly observed for ER-positive
tumors, though a suggestive association was also observed
between hypothyroidism and ER-negative tumors. Consider-
ing that ER-positive tumors make up around 70% of total
breast cancers in all populations, the observed association with
overall breast cancer may reflect the association between thy-
roid dysfunction and ER-positive breast cancer. However, as
data for ER status of the breast tumors were not available in
UK Biobank, this difference could not be replicated in an
independent population and needs confirmation.
The results of the present study are in line with most find-
ings supporting a protective role of high TSH levels in thyroid
cancer. An individual-matched nested case–control study with
1,482 individuals found an inverse association between physi-
ologically high TSH levels and thyroid cancer.30 Similarly,
another small case–control study showed that low levels of
TSH might predispose to thyroid cancer.3 The possible mech-
anism behind the association may be TSH-specific mediated
effect on thyroid tissue through cellular proliferation.31 How-
ever, a retrospective study including 3,791 patients with thy-
roidectomy found that increased serum TSH levels were
related to higher odds of papillary thyroid cancer.32 Among
patients with thyroid nodule, several studies have shown that
high serum TSH levels increase thyroid cancer risk.33,34 In
addition, TSH suppression therapy has been suggested as an
efficient treatment for patients with high-risk thyroid cancer
or recurrent tumor. However, in the present study, we
observed an inverse association between higher TSH levels
and thyroid cancer risk, which is in line with previous
population-based epidemiological and genetic studies.35,36 Dis-
crepancy may be explained by the differences in response to
TSH in normal and cancerous tissues. A nationwide cohort
study found no association of hypothyroidism with thyroid
cancer among 63,143 patients with hypothyroidism compared
to the general population but observed that benign thyroid
disease was associated with higher standardized incidence
ratio of thyroid cancer.37 A possible reason for the null associ-
ation between hypothyroidism and thyroid cancer risk may be
that once diagnosed with hypothyroidism, most patients are
treated for the disorder and no longer hypothyroid, leading to
altered cancer risk. This MR study found a possible inverse
association between genetic liability to hypothyroidism and
thyroid cancer, which needs verification due to a small num-
ber of thyroid cancer cases. In addition, even though there
was no causal association between hyperthyroidism and thy-
roid cancer in our study, a systematic review documented that
pathological hyperthyroid caused by Graves’ disease was asso-
ciated with an increased risk of thyroid cancer.38
Some observational studies have reported associations of
thyroid-related traits with other cancers, such as colorectal,
prostate and lung cancer. Elevated TSH levels, hypothyroidism
and decreased free thyroxine levels have been reported to
associate with a higher risk of prostate cancer.39,40 A large-
scale nested case–control study showed that hyperthyroidism
and untreated hypothyroidism were associated with a mod-
estly elevated risk of colorectal cancer.41 However, results for
lung cancer have been conflicting with a positive5 or null39
association found between free thyroxine levels and lung can-
cer risk. The present MR study showed little evidence in sup-
port for an association of thyroid dysfunction with colorectal,
prostate and lung cancers, except for an inverse association
between TSH levels and prostate cancer. Possible explanations
behind the discrepancy in results across studies may be resid-
ual confounding or reverse causality in the observational stud-
ies or an inadequate power in the present MR study owing to
a small number of cases for these site-specific cancers.
Thyroid hormones are involved in physiological processes
vital to normal metabolism, development and growth, and
hypothyroidism is a known cause of growth retardation.
Hence, not unexpectedly, genetic risk scores for elevated TSH
and decreased free thyroxine levels are associated with
decreased body height.12 Adult height is positively associated
with risk of breast42 and thyroid cancer.43 This suggests that
height (through more cells) might mediate the associations of
thyroid dysfunction with breast and thyroid cancer, or that
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growth processes related to thyroid hormones are driving the
positive association between height and cancer risk. Neverthe-
less, we did not detect any association of the thyroid hor-
mones with other site-specific cancers that are also associated
with height.44,45 Hence, it is reasonable to conclude that
height is not biasing the results through vertical pleiotropy
but that other dominating mechanisms explain the associa-
tions of thyroid dysfunction with breast and thyroid cancer.
Previous studies indicated that body mass index might act as
a mediator in the pathway from thyroid dysfunction to breast
cancer.46 Nevertheless, genetically predicted TSH and free thy-
roxine levels were not associated with BMI using the genetic
risk score analysis12 and we detected no such association of
the liability to hypothyroidism and hyperthyroidism with BMI
either (data not shown).
The exact mechanisms linking thyroid dysfunction to
breast and thyroid cancer have not been clarified. There are
several potential hypotheses, such as uptake and oxidation of
iodine6 and a proliferative effect of triiodothyronine.9 More-
over, it has been shown that thyroxine is a proliferative factor
in vitro for breast cancer cells and that thyroxine can promote
nuclear estrogen receptor alpha-dependent proliferation of
breast cancer cells bearing this receptor.47 Genetic studies
have established a link connecting circulating TSH levels and
thyroid cancer and found that DIRC3, MBIP and NRG1
(encoding the signaling protein neuregulin 1) genes may play
vital roles in this association.36 More studies focusing on the
downstream of certain gene regions, such as key enzymes,
metabolites and signal, transport and receptor proteins, are
warranted for prevention strategy and therapy development.
This is the first MR study comprehensively assessing the
associations of four thyroid function indicators with overall
and 22 site-specific cancers. The major advantage of our study
is the two-sample MR study design, which diminishes
unobserved confounding and reverse causality potentially dis-
torting the results of observational studies. The results were
less likely to be biased by population stratification since we
only used data from European populations, but this confined
the transferability of our findings to other populations.
A major limitation of our study is that the number of cases
was few for several cancers, leading to low precision of the
estimates. Even though our results showed limited evidence
supporting a causal association between thyroid dysfunction
and site-specific cancers except breast and thyroid cancer, we
cannot exclude that we may have missed weak associations
owing to few cases. However, the precision was high in the
analysis of breast cancer by combining the results from the
BCAC and UK Biobank. Furthermore, the thyroid-related
traits showed similar patterns of associations in both BCAC
and UK Biobank, indicating that a false-positive finding is
unlikely. The SNPs used as instrumental variables for the
thyroid-function related traits have been reported to be associ-
ated with other factors, such as height, age at menarche,
obesity-related traits, serum lipids, blood metabolite levels and
serum urate.12 However, considering the biological roles of
thyroid hormones, these factors are more likely to act as
mediators (known as the vertical pleiotropy) in the pathway
from thyroid function to cancer, which will not bias our find-
ings. In addition, the consistency in results across sensitivity
analyses and no detectable directional pleiotropy suggest a
negligible distortion of the results by potential horizontal plei-
otropy. Nevertheless, several thyroid-function related SNPs
were directly associated with thyroid cancer. Thus, we cannot
rule out that there are other direct pathways causing this can-
cer and consequently decreases TSH levels.
In summary, the present two-sample MR study strength-
ened the evidence of causal associations of thyroid function
and dysfunction with risk of overall cancer and breast cancer
(mainly ER-positive tumors). The observed inverse associa-
tions of circulating TSH levels and hypothyroidism with thy-
roid cancer need verification in other MR studies with larger
number of cases. Along with the benefits of thyroid dysfunc-
tion treatment on cancer survival48 and cardiovascular
diseases,49 it is suggested that treatment of subclinical and
diagnosed hyperthyroidism may be an efficient cancer preven-
tion strategy.
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